Rhythm Pharmaceuticals updates obesity pipeline timelines and Phase 3 plan
Rhythm Pharmaceuticals is advancing oral MC4R agonist bivamelagon with a Phase 3 program planned by end-2026 for rare obesity indications. Its RM-718 reported a mean 11.6% BMI drop at 16 weeks in acquired hypothalamic obesity.